SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Oxygen Biotherapeutics, Inc. Engages PPD to Execute Remainder of Phase IIb Clinical Trial to Evaluate the Safety and Tolerability of Oxycyte® in Severe Traumatic Brain Injury